<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/341172</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;341172v1</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;341172</article-id><article-id pub-id-type="other" hwp:sub-type="slug">341172</article-id><article-id pub-id-type="other" hwp:sub-type="tag">341172</article-id><article-version>1.1</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Neuroscience" hwp:journal="biorxiv"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Ketamine disrupts neuromodulatory control of glutamatergic synaptic transmission</article-title></title-group><author-notes hwp:id="author-notes-1"><fn fn-type="present-address" id="n1" hwp:id="fn-1" hwp:rev-id="xref-fn-1-1"><label>2</label><p hwp:id="p-1">Current Address: Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92697</p></fn></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" hwp:id="contrib-1"><name name-style="western" hwp:sortable="Lur Gyorgy"><surname>Lur</surname><given-names>Gyorgy</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref><xref ref-type="fn" rid="n1" hwp:id="xref-fn-1-1" hwp:rel-id="fn-1">2</xref></contrib><contrib contrib-type="author" hwp:id="contrib-2"><name name-style="western" hwp:sortable="Higley Michael J."><surname>Higley</surname><given-names>Michael J.</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2"><label>1</label><institution hwp:id="institution-1">Department of Neuroscience, Kavli Institute for Neuroscience, Yale University School of Medicine</institution>, New Haven, CT 06510, <country>USA</country></aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2018"><year>2018</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2018-06-07T12:26:48-07:00">
    <day>7</day><month>6</month><year>2018</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2018-06-07T12:26:48-07:00">
    <day>7</day><month>6</month><year>2018</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2018-06-07T12:32:04-07:00">
    <day>7</day><month>6</month><year>2018</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2018-06-07T12:32:04-07:00">
    <day>7</day><month>6</month><year>2018</year>
  </pub-date><elocation-id>341172</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2018-06-06"><day>06</day><month>6</month><year>2018</year></date>
<date date-type="rev-recd" hwp:start="2018-06-06"><day>06</day><month>6</month><year>2018</year></date>
<date date-type="accepted" hwp:start="2018-06-07"><day>07</day><month>6</month><year>2018</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2018</copyright-year><license hwp:id="license-1"><p hwp:id="p-2">The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.</p></license></permissions><self-uri xlink:href="341172.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/341172v1.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="341172.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2019/abstracts/341172v1/341172v1.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/341172v1/341172v1.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">Abstract</title><p hwp:id="p-3">A growing body of literature has demonstrated the potential for ketamine in the treatment of major depression. Sub-anesthetic doses produce rapid and sustained changes in depressive behavior, both in patients and rodent models, associated with reorganization of glutamatergic synapses in the prefrontal cortex (PFC). While ketamine is known to regulate NMDA-type glutamate receptors (NMDARs), the full complement of downstream cellular consequences for ketamine administration are not well understood. Here, we combine electrophysiology with 2-photon imaging and glutamate uncaging in acute slices of mouse PFC to further examine how ketamine alters glutamatergic synaptic transmission. We find that four hours after ketamine treatment, glutamatergic synapses themselves are not significantly affected. However, expression levels of the neuromodulatory Regulator of G-protein Signaling (RGS4) are dramatically reduced. This loss of RGS4 activity disrupts the normal compartmentalization of synaptic neuromodulation. Thus, under control conditions, α2 adrenergic receptors and GABA<sub>B</sub> receptors selectively inhibit AMPA-type glutamate receptors (AMPARs) and NMDARs, respectively. After ketamine-induced loss of RGS4 activity, this selectivity is lost, with both modulatory systems broadly inhibiting glutamatergic transmission. These results demonstrate a novel mechanism by which ketamine can influence synaptic signaling and provide new avenues for the exploration of therapeutics directed at treating neuropsychiatric disorders, such as depression.</p></abstract><counts><page-count count="11"/></counts></article-meta></front><body><sec id="s1" hwp:id="sec-1"><title hwp:id="title-2">Introduction</title><p hwp:id="p-4">Major depression, with a lifetime prevalence of 17%, presents a significant psychological and economical burden for both individuals and society (<xref ref-type="bibr" rid="c12" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">Kessler <italic toggle="yes">et al</italic>, 2003</xref>; <xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-1" hwp:rel-id="ref-13">Kessler <italic toggle="yes">et al</italic>, 2005</xref>). Despite enormous efforts to develop effective treatments, available therapeutic interventions have considerable limitations. For example, most antidepressant medications take several weeks to achieve maximal benefit and a significant fraction of patients remain refractory to treatment (<xref ref-type="bibr" rid="c6" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">Fava <italic toggle="yes">et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-1" hwp:rel-id="ref-30">Trivedi <italic toggle="yes">et al</italic>, 2006</xref>). However, recent studies in both clinical and basic science fields have demonstrated promising results using low doses of the drug ketamine. Indeed, sub-anesthetic doses of ketamine produce rapid antidepressant actions within a few hours (<xref ref-type="bibr" rid="c4" hwp:id="xref-ref-4-1" hwp:rel-id="ref-4">Berman <italic toggle="yes">et al</italic>, 2000</xref>; <xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">Krystal <italic toggle="yes">et al</italic>, 2013</xref>; <xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-1" hwp:rel-id="ref-33">Zarate <italic toggle="yes">et al</italic>, 2006</xref>), even in otherwise refractory patients (<xref ref-type="bibr" rid="c22" hwp:id="xref-ref-22-1" hwp:rel-id="ref-22">Mathew <italic toggle="yes">et al</italic>, 2012</xref>). Thus, the potential benefits of this new pharmacological intervention provide great promise for the treatment of major depression.</p><p hwp:id="p-5">Surprisingly, the neurological mechanisms underlying the antidepressant actions of ketamine remain poorly understood. Recent efforts have focused on the regulation of glutamatergic synapses in the prefrontal cortex (PFC) as a potential process by which ketamine modulates behavior. Ketamine itself is an antagonist of NMDA-type glutamate receptors (NMDARs)(<xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">MacDonald <italic toggle="yes">et al</italic>, 1987</xref>), though it may have other actions as well (<xref ref-type="bibr" rid="c27" hwp:id="xref-ref-27-1" hwp:rel-id="ref-27">Sleigh <italic toggle="yes">et al</italic>, 2014</xref>). Acute administration of ketamine produces mild dissociative effects that subside within two hours after administration (<xref ref-type="bibr" rid="c14" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">Krystal <italic toggle="yes">et al</italic>, 1994</xref>), while the antidepressant actions may persist for up to a week (<xref ref-type="bibr" rid="c4" hwp:id="xref-ref-4-2" hwp:rel-id="ref-4">Berman <italic toggle="yes">et al</italic>, 2000</xref>; <xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-2" hwp:rel-id="ref-33">Zarate <italic toggle="yes">et al</italic>, 2006</xref>). In animal models, ketamine stimulates a signaling cascade that produces long-term enhancement of glutamatergic transmission in the PFC, including increased synaptic protein synthesis and increased density of dendritic spines, the structural sites of individual excitatory inputs (<xref ref-type="bibr" rid="c5" hwp:id="xref-ref-5-1" hwp:rel-id="ref-5">Duman and Aghajanian, 2012</xref>; <xref ref-type="bibr" rid="c8" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">Holtmaat and Svoboda, 2009</xref>; <xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">Li <italic toggle="yes">et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">Moghaddam <italic toggle="yes">et al</italic>, 1997</xref>). Moreover, these synaptic changes persist for several days after administration (<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-2" hwp:rel-id="ref-17">Li <italic toggle="yes">et al</italic>, 2010</xref>).</p><p hwp:id="p-6">The cellular mechanisms underlying these alterations in synaptic structure and function are unclear, and a variety of signaling pathways have been implicated in linking NMDAR blockade to long-term alteration of glutamatergic signaling, including the mammalian target of rapamycin (mTOR) and brain-derived neurotrophic factor (BDNF) (<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">Autry <italic toggle="yes">et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-3" hwp:rel-id="ref-17">Li <italic toggle="yes">et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-1" hwp:rel-id="ref-19">Liu <italic toggle="yes">et al</italic>, 2012</xref>). Both these processes have been shown to regulate the growth and stability of glutamatergic synapses (<xref ref-type="bibr" rid="c10" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">Jourdi <italic toggle="yes">et al</italic>, 2009</xref>; <xref ref-type="bibr" rid="c29" hwp:id="xref-ref-29-1" hwp:rel-id="ref-29">Takei <italic toggle="yes">et al</italic>, 2004</xref>). However, ketamine has also been linked to alterations in inhibitory GABAergic signaling, both directly and indirectly by disrupting activity in inhibitory interneurons (<xref ref-type="bibr" rid="c9" hwp:id="xref-ref-9-1" hwp:rel-id="ref-9">Homayoun and Moghaddam, 2007</xref>; <xref ref-type="bibr" rid="c11" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">Kavalali and Monteggia, 2012</xref>; <xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-1" hwp:rel-id="ref-32">Wohleb <italic toggle="yes">et al</italic>, 2017</xref>).</p><p hwp:id="p-7">A recent study suggested that acute administration of ketamine might also impact the function of the protein regulator of G-protein signaling type-4 (RGS4) (<xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-1" hwp:rel-id="ref-28">Stratinaki <italic toggle="yes">et al</italic>, 2013</xref>). RGS4 is a GTPase activating protein that accelerates the hydrolysis of GTP to GDP following the activation of G proteins by a variety of ligand-receptor interactions (<xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">Bansal <italic toggle="yes">et al</italic>, 2007</xref>; <xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-1" hwp:rel-id="ref-31">Watson <italic toggle="yes">et al</italic>, 1996</xref>). Behavioral studies in mice lacking RGS4 demonstrated that this enzyme can act as a key negative modulator of ketamine-mediated antidepressant actions (<xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-2" hwp:rel-id="ref-28">Stratinaki <italic toggle="yes">et al</italic>, 2013</xref>), and ketamine itself is capable of reducing expression levels of RGS4 in the PFC. We previously found that RGS4 plays a crucial role in regulating the neuromodulation of glutamatergic synapses in the PFC (<xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">Lur and Higley, 2015</xref>). Our data showed that the specificity of adrenergic and GABAergic control over AMPA- and NMDA-type glutamate receptors, respectively, is abolished following pharmacological blockade of RGS4 function.</p><p hwp:id="p-8">As neuromodulation may play a key role in normal prefrontal function, we investigated whether ketamine might disrupt the regulation of glutamate receptors in the PFC. Using a combination of electrophysiology, 2-photon imaging, and glutamate uncaging in acute slices from the mouse PFC, we found that a single dose of ketamine did not alter basal function of postsynaptic glutamate receptors. However, ketamine did produce a substantial reduction in prefrontal RGS4 expression in the PFC and abolished the specificity of adrenergic and GABAergic modulation of excitatory synapses. Thus, our work suggests a novel mechanism by which acute ketamine can influence glutamatergic signaling and potentially contribute to its antidepressant actions.</p></sec><sec id="s2" hwp:id="sec-2"><title hwp:id="title-3">Materials and Methods</title><sec id="s2a" hwp:id="sec-3"><title hwp:id="title-4">Animals and drug treatment</title><p hwp:id="p-9">All animal handling was performed in accordance with guidelines approved by the Yale Institutional Animal Care and Use Committee and federal guidelines. Wild-type C57/Bl6 mice (P22-36) were injected i.p. with either saline vehicle or ketamine (15 mg/kg) 4 hours prior to experiments.</p></sec><sec id="s2b" hwp:id="sec-4"><title hwp:id="title-5">Slice Preparation</title><p hwp:id="p-10">For glutamate uncaging experiments, we prepared acute prefrontal cortical (PFC) slices as previously described (Lur <italic toggle="yes">et al</italic>, 2015). Briefly, mice were anesthetized with isoflurane and decapitated, and coronal slices (300 μm) were cut in ice-cold solution containing (in mM): 110 choline, 25 NaHCO<sub>3</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 3 KCl, 7 MgCl<sub>2</sub>, 0.5 CaCl<sub>2</sub>, 10 glucose, 11.6 sodium ascorbate and 3.1 sodium pyruvate, bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. Slices containing the prelimbicinfralimbic regions of the PFC were then transferred to artificial cerebrospinal fluid (ACSF) containing (in mM): 126 NaCl, 26 NaHCO<sub>3</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 3 KCl, 1 MgCl<sub>2</sub>, 2 CaCl<sub>2</sub>, 10 glucose, 0.4 sodium ascorbate, 2 sodium pyruvate and 3 myo-inositol, bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. After an incubation period of 15 min at 34°C, the slices were maintained at 22–24°C for at least 20 min before use.</p></sec><sec id="s2c" hwp:id="sec-5"><title hwp:id="title-6">Electrophysiology and imaging</title><p hwp:id="p-11">All experiments were conducted at near physiological temperature (32-34°C) in a submersion-type recording chamber. Whole-cell recordings in voltage clamp mode were obtained from layer 5 pyramidal cells (400- 500 μm from the pial surface) identified with infrared differential interference contrast. Glass electrodes (1.8-3.0 MΩ) were filled with internal solution containing (in mM): 135 CsMeSO<sub>3</sub>, 10 HEPES, 4 MgCl<sub>2</sub>, 4 Na<sub>2</sub>ATP, 0.4 NaGTP, 10 sodium creatine phosphate and 0.2% Neurobiotin (Vector Laboratories) adjusted to pH 7.3 with CsOH. Red-fluorescent Alexa Fluor-594 (10 μM, Invitrogen) and the green-fluorescent calcium (Ca2+)-sensitive Fluo-5F (300 μM, Invitrogen) were included in the pipette solution. Neurons were filled via the patch electrode for 10 min before imaging. Series resistance was 10-22 MΩ and uncompensated. Electrophysiological recordings were made using a Multiclamp 700B amplifier (Molecular Devices), filtered at 4 kHz, and digitized at 10 kHz. Typically, 7-10 trials were averaged into each response.</p><p hwp:id="p-12">2-photon imaging was accomplished with a custom-modified Olympus BX51-WI microscope (Olympus, Japan), including components manufactured by Mike’s Machine Company (<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">Higley and Sabatini, 2010</xref>). Fluorophores were excited using 840 nm light from a pulsed titanium-sapphire laser (Ultra2, Coherent). Emitted green and red photons were separated with appropriate optics (Chroma, Semrock) and collected by photomultiplier tubes (Hamamatsu).</p><p hwp:id="p-13">For Ca2+ imaging, signals were collected during 500 Hz line scans across a spine. Ca2+ signals were first quantified as increases in green fluorescence from baseline normalized to the average red fluorescence (AG/R). We then expressed fluorescence changes as the fraction of the G/R ratio measured in saturating Ca2+ (ΔG/G<sub>sat</sub>)(<xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-2" hwp:rel-id="ref-20">Lur and Higley 2015</xref>).</p></sec><sec id="s2d" hwp:id="sec-6"><title hwp:id="title-7">2-Photon Glutamate uncaging</title><p hwp:id="p-14">For focal stimulation of single dendritic spines, we used 2-photon laser uncaging of glutamate (2PLU). To photorelease glutamate, a second Ti-Sapphire laser tuned to 720 nm was introduced into the light path using polarization optics. Laser power was calibrated for each spine by directing the uncaging spot to the middle of the spine head. We adjusted uncaging power to achieve 50% photobleaching of the Alexa 594 dye filling the spine (Lur <italic toggle="yes">et al</italic>, 2015). The power used for 2PLU ranged from 8 to 25 mW, pulse duration was 2 ms. For synaptic stimulation, we typically uncaged glutamate at 3-4 separate locations around a single spine head to find a “hot spot”, the place of the largest response. Our previous measurements indicate that this stimulus resulted in uEPSCs similar in size and kinetics to spontaneous mEPSCs (Lur <italic toggle="yes">et al</italic>, 2015).</p></sec><sec id="s2e" hwp:id="sec-7"><title hwp:id="title-8">Data acquisition and analysis</title><p hwp:id="p-15">Imaging and physiology data were acquired using National Instruments data acquisition boards and custom software written in MATLAB (Mathworks, (<xref ref-type="bibr" rid="c25" hwp:id="xref-ref-25-1" hwp:rel-id="ref-25">Pologruto <italic toggle="yes">et al</italic>, 2003</xref>)). Off-line analysis was performed using custom routines written in MATLAB and IgorPro (Wavemetrics). AMPAR-mediated EPSC amplitudes were calculated by finding the peak of the current traces and averaging the values within a 0.3 ms window. NMDARmediated currents were measured in a 3 ms window around the peak. 2PLU-evoked ΔCa2+ was calculated as the average ΔG/G<sub>sat</sub> over a 100 ms window, starting 5 ms after the uncaging event. Statistical comparisons were conducted in GraphPad Prism 5. All data were analyzed using one-way analysis of variance (ANOVA)-tests corrected for multiple comparisons (Tukey).</p></sec><sec id="s2f" hwp:id="sec-8"><title hwp:id="title-9">Pharmacology and reagents</title><p hwp:id="p-16">2PLU experiments were performed in normal ACSF supplemented with MNIglutamate (2.5 mM) and D-serine (10 μM). To isolate AMPAR-mediated currents in voltage clamp experiments, we added TTX (1 μM) to block sodium channels, picrotoxin (50 μM) to block GABA<sub>A</sub> receptors, CGP55845 (3 μM) to block GABA<sub>B</sub> receptors, and CPP (10 μM) to block NMDA-type glutamate receptors to the ACSF. To isolate NMDAR-mediated currents, we modified our original ACSF to contain 0 mM Mg and 3 mM Ca2+ and included TTX (1 μM), picrotoxin (50 μM), CGP55845 (3 μM), and NBQX (10 μM) to block AMPA-type glutamate receptors. GPCR agonists were applied 5-7 minutes prior to data collection. All compounds and salts were from Tocris and Sigma, respectively.</p></sec><sec id="s2g" hwp:id="sec-9"><title hwp:id="title-10">Western blot analysis</title><p hwp:id="p-17">For RGS4 western blot analysis, we prepared 300 μm thick brain slices containing the PFC from p22-42 C57/bl6 mice as described above. Following the recovery period, the prelimbic region of the prefrontal cortex was dissected out of the slices on ice. Tissue samples were homogenized and sonicated in ice cold lysis buffer containing 20 mM Tris, 1 mM EDTA and 1x Halt protease and phosphatase inhibitor cocktail (Thermo Scientific) and 0.5% SDS, pH 8.0. After a 10-minute centrifugation at 14000 rpm, the supernatant was collected, and protein content was determined using Pierce BCA Protein Assay (Thermo Scientific). Samples containing equal amounts of protein were separated on a 6% poly-acrylamide gel and transferred to PVDF membranes. After blocking for 1h at room temperature with 3% non-fat milk and 0.02% Na-azide in Tris buffered salt solution with 0.05% Tween 20 (TBST), membranes were immunoreacted with primary antibody against RGS4 (Millipore, RBT17) in 1% milk and 0.02% Naazide in TBST, 1:1000, overnight. After washing off excess primary antibody and incubation with the appropriate HRP conjugated secondary antibody (GE Healthcare, UK) for 2 hours at room temperature in TBST, bands were visualized using HyGlo Chemiluminescent HRP Antibody Detection Reagent (Denville Scientific Inc.) and exposed onto autoradiography film (Denville Scientific Inc.). Membranes were then stripped from antibodies using Restore Plus Western Blot Stripping Buffer (15 minutes at room temperature, Thermo Scientific), re-blocked and immunoreacted with anti-β-tubulin (SIGMA) primary antibody followed by the appropriate HRP-secondary antibody to establish total amount β-tubulin in the samples. Autoradiography films were developed in a Kodak automatic developer, then scanned and analyzed with ImageJ. RGS4 expression was quantified as RGS4 / β-tubulin.</p></sec></sec><sec id="s3" hwp:id="sec-10"><title hwp:id="title-11">Results</title><p hwp:id="p-18">To investigate the consequences of ketamine for glutamatergic signaling, we injected mice with either a single dose of ketamine (15 mg/kg) or saline vehicle. At four hours post-injection, we prepared acute brain slices from the medial prefrontal cortex (PFC) of the injected animals and made whole cell voltage clamp recordings from layer 5 pyramidal neurons in the prelimbic region (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Figure 1A</xref>). We measured excitatory postsynaptic currents (EPSCs) evoked by 2-photon laser uncaging (2PLU) of glutamate onto spines along the basal dendrites, while simultaneously monitoring intra-spine Ca2+ transients using 2-photon laser scanning microscopy (2PLSM)(<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-2" hwp:rel-id="F1">Figure 1B</xref>). We found no difference in AMPAR-mediated EPSCs between vehicle (20.9 ± 1.9 pA, n= 31 spines) and ketamine (21.0 ± 1.4 pA, n=33 spines, p=0.96, t-test, <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-3" hwp:rel-id="F1">Figures 1C</xref> and <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-1" hwp:rel-id="F4">4A</xref>) groups. Notably, we also failed to observe alterations in NMDAR-mediated currents (vehicle: 22.9 ± 2 pA, n=31 spines, ketamine: 21.4 ± 1.8 pA, n=31 spines, p=0.59, t-test) or Ca2+ transients (vehicle: 0.52 ± 0.02 ΔG/Gsat, ketamine: 0.54 ± 0.02 ΔG/G<sub>sat</sub>, p=0.31, t-test, <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-4" hwp:rel-id="F1">Figures 1C</xref> and <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-2" hwp:rel-id="F4">4B</xref>), indicating the absence of persistent NMDAR blockade. Overall, our results suggest that ketamine produces minimal postsynaptic change in glutamatergic synapses at this time point.</p><fig id="fig1" position="float" orientation="portrait" fig-type="figure" hwp:id="F1" hwp:rev-id="xref-fig-1-1 xref-fig-1-2 xref-fig-1-3 xref-fig-1-4"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;341172v1/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Figure 1.</label><caption hwp:id="caption-1"><title hwp:id="title-12">Ketamine does not affect glutamatergic transmission 4 hours post treatment.</title><p hwp:id="p-19">(A) A 2-photon image of a layer 5 pyramidal neuron visualized by Alexa 594 flourescence. White box highlights the extent of the basal dendritic arbor searched for spines. (Bi) Image of a dendritic spine. White asterisk shows the uncaging location. Fluorescence intensity was measured in a line scan highlighted by the yellow dashed line. (Bii) Chronogram showing the change in green fluorescence indicating a transient increase of intracellular Ca2+ concentration in the spine head in response to glutamate uncaging (arrowhead). (Ci) Mean AMPAR-mediated uEPSCs in vehicle (black) and in ketamine (blue) treated animals ± SEM (shaded areas). (Cii) 2PLU-evoked NMDAR currents and (Ciii) Ca2+ transients in vehicle (black) and in ketamine treated animals (blue), mean (solid lines) ± SEM (shaded areas). *: p&lt;0.05, unpaired t-test.</p></caption><graphic xlink:href="341172_fig1" position="float" orientation="portrait" hwp:id="graphic-1"/></fig><p hwp:id="p-20">Endogenous control of glutamatergic transmission by GPCRs plays a central role in prefrontal function. We previously showed that both noradrenergic and GABAergic modulation of glutamatergic synapses is influenced by the activity of the small GTPase RGS4 (Lur <italic toggle="yes">et al</italic>, 2015), whose expression levels are thought to be regulated by antidepressants including ketamine (<xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-3" hwp:rel-id="ref-28">Stratinaki <italic toggle="yes">et al</italic>, 2013</xref>). To examine the consequences of acute ketamine on RGS4 function in the prefrontal cortex, we first prepared tissue samples from the prelimbic region four hours after animals were injected with either ketamine or saline. Western-blot analysis confirmed a 50 ± 0.1% reduction of RGS4 protein expression (p=0.0016, n=5 animals, unpaired t-test, <xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Figure 2A and B</xref>), suggesting that ketamine may disrupt neuromodulation at glutamatergic synapses.</p><fig id="fig2" position="float" orientation="portrait" fig-type="figure" hwp:id="F2" hwp:rev-id="xref-fig-2-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;341172v1/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Figure 2.</label><caption hwp:id="caption-2"><title hwp:id="title-13">Acute ketamine treatment reduces prefrontal RGS4 expression.</title><p hwp:id="p-21">(A) Example western blot of RGS4 and β-tubulin in vehicle- versus ketamine-treated mice. (B) Quantification of RGS4 levels in vehicle (black) and ketamine (blue) treated mice. Bars show mean ± SEM, *: p&lt;0.05, unpaired t-test.</p></caption><graphic xlink:href="341172_fig2" position="float" orientation="portrait" hwp:id="graphic-2"/></fig><p hwp:id="p-22">Activation of alpha2 adrenergic receptors and GABAB receptors negatively modulate AMPARs and NMDARs, respectively via downregulation of protein kinase A (PKA) activity (Lur <italic toggle="yes">et al</italic>, 2015). Moreover, this selective coupling of GPCRs to distinct synaptic proteins requires RGS4 and is lost following small molecule antagonism of RGS4 activity (Lur <italic toggle="yes">et al</italic>, 2015). We therefore asked whether ketamine produces similar dysregulation of synaptic modulation. First, we confirmed that, in saline-injected mice, application of the alpha2 adrenergic agonist guanfacine significantly reduced 2PLU-evoked AMPAR-mediated currents (to 13.0 ± 0.8 pA, n=25 spines, one-way ANOVA (F=9.93, p&lt;0.0001), Tukey’s multiple comparison test p&lt;0.01) but did not alter 2PLU-evoked NMDAR-mediated currents (22.3 ± 2 pA, n=33 spines, one-way ANOVA (F=6.53, p=0.0004), Tukey’s multiple comparison test p&gt;0.05, <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-1" hwp:rel-id="F3">Figures 3Aii</xref> and <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-3" hwp:rel-id="F4">4B</xref>) or ΔCa2+ (0.54 ± 0.02 ΔG/G<sub>sat</sub>, one-way ANOVA (F=8.1, p&lt;0.0001), Tukey’s multiple comparison test p&gt;0.05, <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-2" hwp:rel-id="F3">Figures 3A</xref>, <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-4" hwp:rel-id="F4">4</xref>). Conversely, application of the GABAB agonist baclofen did not alter 2PLUevoked AMPAR-mediated currents (20.3 ± 1.5 pA, n=32 spines, one-way ANOVA (F=10.3, p&lt;0.0001), Tukey’s multiple comparison test p&gt;0.05) or NMDAR currents (23.0 ± 2.5 pA, n=25 spines, one-way ANOVA (F=5.01, p=0.0008), Tukey’s multiple comparison test p&gt;0.05) but reduced NMDAR-dependent ΔCa2+ (to 0.39 ± 0.01 ΔG/G<sub>sat</sub>, one-way ANOVA (F=12.11, p&lt;0.0001), Tukey’s multiple comparison test p&lt;0.001, <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-3" hwp:rel-id="F3">Figures 3B</xref>, <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-5" hwp:rel-id="F4">4</xref>).</p><fig id="fig3" position="float" orientation="portrait" fig-type="figure" hwp:id="F3" hwp:rev-id="xref-fig-3-1 xref-fig-3-2 xref-fig-3-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;341172v1/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>Figure 3.</label><caption hwp:id="caption-3"><title hwp:id="title-14">Differential control of excitatory transmission by α2- and GABAb receptors.</title><p hwp:id="p-23">(Ai) Mean AMPAR-mediated uEPSCs in control (black) and guanfacine (orange) ± SEM (shaded areas). (Aii) 2PLU-evoked NMDAR currents and (Aiii) Ca2+ transients in control (black) and guanfacine (orange), mean (solid lines) ± SEM (shaded areas). (Bi) Mean AMPAR-mediated uEPSCs in control (black) and baclofen (magenta) ± SEM (shaded areas). (Bii) NMDAR-mediated uEPSCs and (Biii) Ca2+ transients in control (black) and baclofen (magenta) ± SEM (shaded areas). *: p&lt;0.05, unpaired t-test.</p></caption><graphic xlink:href="341172_fig3" position="float" orientation="portrait" hwp:id="graphic-3"/></fig><p hwp:id="p-24">We then performed similar experiments in mice injected four hours prior to slice preparation with ketamine. In contrast to saline-treated animals, AMPAR-mediated currents were significantly reduced by baclofen (to 12.1 ± 1 pA, n=33 spines, one-way ANOVA (F=9.93, p&lt;0.0001), Tukey’s multiple comparison test p&lt;0.001, <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-6" hwp:rel-id="F4">Figure 4A</xref>) while guanfacine significantly reduced both NMDAR currents (to 13.6 ± 1.3 pA, n=37 spines, one-way ANOVA (F=5.0, p=0.0008), Tukey’s multiple comparison test p&lt;0.05, <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-7" hwp:rel-id="F4">Figure 4B</xref>) and ΔCa2+ (to 0.42 ± 0.02 ΔG/G<sub>sat</sub>, one-way ANOVA (F=12.1, p&lt;0.0001), Tukey’s multiple comparison test p&lt;0.001, <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-8" hwp:rel-id="F4">Figure 4C</xref>). We have previously shown that blocking RGS4 function does not alter the effect of guanfacine on AMPARs or the baclofen induced reduction of NMDAR dependent Ca2+ influx. We have also shown that multiple methods of RGS4 inhibition introduced baclofen induced reduction of NMDAR currents (Lur <italic toggle="yes">et al</italic>, 2015). Our current results match these previous observations. Overall, these findings demonstrate that ketamine exposure disrupts neuromodulation of glutamatergic signaling in the absence of direct actions on synaptic potency.</p><fig id="fig4" position="float" orientation="portrait" fig-type="figure" hwp:id="F4" hwp:rev-id="xref-fig-4-1 xref-fig-4-2 xref-fig-4-3 xref-fig-4-4 xref-fig-4-5 xref-fig-4-6 xref-fig-4-7 xref-fig-4-8"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;341172v1/FIG4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F4</object-id><object-id pub-id-type="publisher-id">fig4</object-id><label>Figure 4.</label><caption hwp:id="caption-4"><title hwp:id="title-15">Ketamine treatment eliminates compartmentalized neuromodulation.</title><p hwp:id="p-25">(A) Bars represent mean amplitude ± SEM of AMPAR currents, (B) NMDARmediated currents and (C) NMDAR-mediated Ca2+ transients in control (gray), in guanfacine (orange) or in baclofen (magenta) from vehicle- versus ketaminetreated mice. *: p&lt;0.05, Tukey’s multiple comparison test.</p></caption><graphic xlink:href="341172_fig4" position="float" orientation="portrait" hwp:id="graphic-4"/></fig></sec><sec id="s4" hwp:id="sec-11"><title hwp:id="title-16">Discussion</title><p hwp:id="p-26">In our present study, we demonstrate that a single sub-anesthetic dose of ketamine produces significant dysregulation of neuromodulatory control over glutamatergic signaling in the mouse prefrontal cortex. Specifically, following ketamine administration, adrenergic and GABAergic inputs inhibit NMDARs and AMPARs, respectively, a phenomenon that does not occur in untreated animals. Our results suggest this process is mediated by acute reduction in expression levels of the small GTPase RGS4, which we previously showed prevents neuromodulatory cross-talk in dendritic spines (Lur <italic toggle="yes">et al</italic>, 2015). Our findings thus extend our knowledge of targets for ketamine that may contribute to or interact with its antidepressant actions in vivo.</p><p hwp:id="p-27">RGS4 is a small GTPase that limits signaling through G protein-coupled receptor pathways by accelerating the hydrolysis of GTP to GDP (<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">Arshavsky and Pugh, 1998</xref>; <xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-2" hwp:rel-id="ref-3">Bansal <italic toggle="yes">et al</italic>, 2007</xref>; <xref ref-type="bibr" rid="c34" hwp:id="xref-ref-34-1" hwp:rel-id="ref-34">Zhong <italic toggle="yes">et al</italic>, 2003</xref>). Under control conditions, this activity produces microdomains within single dendritic spines that restricts neuromodulatory cascades. For example, adrenergic α2 receptors and GABAB receptors are both coupled to G<sub>i</sub> proteins that down-regulate cAMP production and PKA activity. Surprisingly, we found that both receptors are present in single spines but are selectively able to negatively modulate AMPARs and NMDARs, respectively (Lur <italic toggle="yes">et al</italic>, 2015). However, when RGS4 is blocked pharmacologically, this microdomain organization breaks down, leading to cross talk between the neuromodulatory signaling cascades (Lur <italic toggle="yes">et al</italic>, 2015; <xref ref-type="bibr" rid="c34" hwp:id="xref-ref-34-2" hwp:rel-id="ref-34">Zhong <italic toggle="yes">et al</italic>, 2003</xref>). Remarkably, a single dose of ketamine appears to produce substantial loss of RGS4 expression within a few hours (<xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-4" hwp:rel-id="ref-28">Stratinaki <italic toggle="yes">et al</italic>, 2013</xref>), a finding confirmed in our present study, suggesting this protein is rapidly turned over in cortical neurons. Consistent with our previous results using small molecule inhibitors of RGS4, ketamineinduced down-regulation of RGS4 expression also produces aberrant cross-talk between modulatory signals and glutamate receptors.</p><p hwp:id="p-28">Previous studies looking at the effects of ketamine administration 24 hours post-exposure showed increased amplitude for spontaneous EPSCs in layer 5 PNs. This result was linked to an increase in both spine volume and the density of mature spines and attributed to changes in postsynaptic gene expression (<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-4" hwp:rel-id="ref-17">Li <italic toggle="yes">et al</italic>, 2010</xref>). In contrast, our results indicate that four hours after ketamine administration, basal postsynaptic glutamatergic signaling through either AMPARs or NMDARs is unaltered. This difference may be due to a longer time window required for altered synaptic gene expression to manifest. Since spontaneous mEPSC recordings do not distinguish between pre- and post synaptic effects it is also possible that the ketamine induced changes reported by Li et al. are presynaptic. Our 2PLU experiments circumvent this caveat by exclusively stimulating postsynaptic glutamate receptors.</p><p hwp:id="p-29">Acute doses of ketamine have been shown to produce rapid synaptic reorganization in the prefrontal cortex that coincides with antidepressant actions in rodent models (Kavalali <italic toggle="yes">et al</italic>, 2012; <xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-1" hwp:rel-id="ref-18">Li <italic toggle="yes">et al</italic>, 2011</xref>). Interestingly, these effects are thought to be mediated through inhibition of NMDARs by ketamine (<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-2" hwp:rel-id="ref-18">Li <italic toggle="yes">et al</italic>, 2011</xref>). This hypothesis is supported by evidence that other NMDAR blockers can produce similar synaptic and behavioral effects (<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-2" hwp:rel-id="ref-2">Autry <italic toggle="yes">et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-3" hwp:rel-id="ref-18">Li <italic toggle="yes">et al</italic>, 2011</xref>). Loss of NMDAR signaling may activate both mTOR and BDNF signaling pathways that may provide molecular mechanisms for synaptic changes following ketamine (<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-3" hwp:rel-id="ref-2">Autry <italic toggle="yes">et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="c10" hwp:id="xref-ref-10-2" hwp:rel-id="ref-10">Jourdi <italic toggle="yes">et al</italic>, 2009</xref>; <xref ref-type="bibr" rid="c16" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">Lepack <italic toggle="yes">et al</italic>, 2014</xref>; <xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-5" hwp:rel-id="ref-17">Li <italic toggle="yes">et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-2" hwp:rel-id="ref-19">Liu <italic toggle="yes">et al</italic>, 2012</xref>; <xref ref-type="bibr" rid="c29" hwp:id="xref-ref-29-2" hwp:rel-id="ref-29">Takei <italic toggle="yes">et al</italic>, 2004</xref>). Our findings suggest the intriguing possibility that ketamine may also suppress NMDAR activity by broadening the consequences of adrenergic signaling. That is, following ketamine, α2 receptors may further suppress these glutamate receptors. Thus, activation of adrenergic signaling could be an adjunct approach to boost the effects of ketamine. Indeed, guanfacine alone exhibits antidepressant activity in human studies (<xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">Mineur <italic toggle="yes">et al</italic>, 2015</xref>; <xref ref-type="bibr" rid="c26" hwp:id="xref-ref-26-1" hwp:rel-id="ref-26">Ramos and Arnsten, 2007</xref>).</p><p hwp:id="p-30">In conclusion, our current findings provide novel evidence that acute ketamine can influence glutamatergic transmission in the mouse prefrontal cortex via down-regulation of RGS4 expression and dysregulation of neuromodulatory signaling. These results expand our view of the downstream actions of ketamine and suggest that inhibition of NMDARs by α2 adrenergic signaling may provide benefit in models of depression when delivered alongside sub-anesthetic doses of ketamine.</p></sec></body><back><sec hwp:id="sec-12"><title hwp:id="title-17">Funding and Disclosure</title><p hwp:id="p-31">The authors declare that we have no competitive financial conflicts of interest associated with this work. These studies were funded by grants from the Brain and Behavior Research Foundation (NARSAD Young Investigator Award, G.L.), the Smith Family Foundation (M.J.H.), and the NIH (R01 MH099045, M.J.H.).</p></sec><ack hwp:id="ack-1"><title hwp:id="title-18">Acknowledgements</title><p hwp:id="p-32">The authors wish to thank Dr. Jessica A. Cardin and members of the Higley laboratory for helpful discussions during the preparation of this manuscript.</p></ack><ref-list hwp:id="ref-list-1"><title hwp:id="title-19">References</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="Arshavsky VY"><surname>Arshavsky</surname> <given-names>VY</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pugh EN Jr"><surname>Pugh</surname> <given-names>EN</given-names>, <suffix>Jr</suffix></string-name>. (<year>1998</year>). <article-title hwp:id="article-title-2">Lifetime regulation of G protein-effector complex: emerging importance of RGS proteins</article-title>. <source hwp:id="source-1">Neuron</source> <volume>20</volume>(<issue>1</issue>): <fpage>11</fpage>–<lpage>14</lpage>.</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1 xref-ref-2-2 xref-ref-2-3"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Autry AE"><surname>Autry</surname> <given-names>AE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Adachi M"><surname>Adachi</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nosyreva E"><surname>Nosyreva</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Na ES"><surname>Na</surname> <given-names>ES</given-names></string-name>, <string-name name-style="western" hwp:sortable="Los MF"><surname>Los</surname> <given-names>MF</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cheng PF"><surname>Cheng</surname> <given-names>PF</given-names></string-name>, <etal>et al</etal> (<year>2011</year>). <article-title hwp:id="article-title-3">NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses</article-title>. <source hwp:id="source-2">Nature</source> <volume>475</volume>(<issue>7354</issue>): <fpage>91</fpage>–<lpage>95</lpage>.</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1 xref-ref-3-2"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Bansal G"><surname>Bansal</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Druey KM"><surname>Druey</surname> <given-names>KM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Xie Z"><surname>Xie</surname> <given-names>Z</given-names></string-name> (<year>2007</year>). <article-title hwp:id="article-title-4">R4 RGS proteins: regulation of G-protein signaling and beyond</article-title>. <source hwp:id="source-3">Pharmacol Ther</source> <volume>116</volume>(<issue>3</issue>): <fpage>473</fpage>–<lpage>495</lpage>.</citation></ref><ref id="c4" hwp:id="ref-4" hwp:rev-id="xref-ref-4-1 xref-ref-4-2"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Berman RM"><surname>Berman</surname> <given-names>RM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cappiello A"><surname>Cappiello</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Anand A"><surname>Anand</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Oren DA"><surname>Oren</surname> <given-names>DA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Heninger GR"><surname>Heninger</surname> <given-names>GR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Charney DS"><surname>Charney</surname> <given-names>DS</given-names></string-name>, <etal>et al</etal> (<year>2000</year>). <article-title hwp:id="article-title-5">Antidepressant effects of ketamine in depressed patients</article-title>. <source hwp:id="source-4">Biol Psychiatry</source> <volume>47</volume>(<issue>4</issue>): <fpage>351</fpage>–<lpage>354</lpage>.</citation></ref><ref id="c5" hwp:id="ref-5" hwp:rev-id="xref-ref-5-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Duman RS"><surname>Duman</surname> <given-names>RS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Aghajanian GK"><surname>Aghajanian</surname> <given-names>GK</given-names></string-name> (<year>2012</year>). <article-title hwp:id="article-title-6">Synaptic dysfunction in depression: potential therapeutic targets</article-title>. <source hwp:id="source-5">Science</source> <volume>338</volume>(<issue>6103</issue>): <fpage>68</fpage>–<lpage>72</lpage>.</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Fava M"><surname>Fava</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rush AJ"><surname>Rush</surname> <given-names>AJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Alpert JE"><surname>Alpert</surname> <given-names>JE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Balasubramani GK"><surname>Balasubramani</surname> <given-names>GK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wisniewski SR"><surname>Wisniewski</surname> <given-names>SR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Carmin CN"><surname>Carmin</surname> <given-names>CN</given-names></string-name>, <etal>et al</etal> (<year>2008</year>). <article-title hwp:id="article-title-7">Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report</article-title>. <source hwp:id="source-6">Am J Psychiatry</source> <volume>165</volume>(<issue>3</issue>): <fpage>342</fpage>–<lpage>351</lpage>.</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Higley MJ"><surname>Higley</surname> <given-names>MJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sabatini BL"><surname>Sabatini</surname> <given-names>BL</given-names></string-name> (<year>2010</year>). <article-title hwp:id="article-title-8">Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors</article-title>. <source hwp:id="source-7">Nat Neurosci</source> <volume>13</volume>(<issue>8</issue>): <fpage>958</fpage>–<lpage>966</lpage>.</citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Holtmaat A"><surname>Holtmaat</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Svoboda K"><surname>Svoboda</surname> <given-names>K</given-names></string-name> (<year>2009</year>). <article-title hwp:id="article-title-9">Experience-dependent structural synaptic plasticity in the mammalian brain</article-title>. <source hwp:id="source-8">Nat Rev Neurosci</source> <volume>10</volume>(<issue>9</issue>): <fpage>647</fpage>–<lpage>658</lpage>.</citation></ref><ref id="c9" hwp:id="ref-9" hwp:rev-id="xref-ref-9-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Homayoun H"><surname>Homayoun</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Moghaddam B"><surname>Moghaddam</surname> <given-names>B</given-names></string-name> (<year>2007</year>). <article-title hwp:id="article-title-10">NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons</article-title>. <source hwp:id="source-9">J Neurosci</source> <volume>27</volume>(<issue>43</issue>): <fpage>11496</fpage>–<lpage>11500</lpage>.</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1 xref-ref-10-2"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Jourdi H"><surname>Jourdi</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hsu YT"><surname>Hsu</surname> <given-names>YT</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhou M"><surname>Zhou</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Qin Q"><surname>Qin</surname> <given-names>Q</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bi X"><surname>Bi</surname> <given-names>X</given-names></string-name>, <string-name name-style="western" hwp:sortable="Baudry M"><surname>Baudry</surname> <given-names>M</given-names></string-name> (<year>2009</year>). <article-title hwp:id="article-title-11">Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation</article-title>. <source hwp:id="source-10">J Neurosci</source> <volume>29</volume>(<issue>27</issue>): <fpage>8688</fpage>–<lpage>8697</lpage>.</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Kavalali ET"><surname>Kavalali</surname> <given-names>ET</given-names></string-name>, <string-name name-style="western" hwp:sortable="Monteggia LM"><surname>Monteggia</surname> <given-names>LM</given-names></string-name> (<year>2012</year>). <article-title hwp:id="article-title-12">Synaptic mechanisms underlying rapid antidepressant action of ketamine</article-title>. <source hwp:id="source-11">Am J Psychiatry</source> <volume>169</volume>(<issue>11</issue>): <fpage>1150</fpage>–<lpage>1156</lpage>.</citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Kessler RC"><surname>Kessler</surname> <given-names>RC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Berglund P"><surname>Berglund</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Demler O"><surname>Demler</surname> <given-names>O</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jin R"><surname>Jin</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Koretz D"><surname>Koretz</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Merikangas KR"><surname>Merikangas</surname> <given-names>KR</given-names></string-name>, <etal>et al</etal> (<year>2003</year>). <article-title hwp:id="article-title-13">The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)</article-title>. <source hwp:id="source-12">JAMA</source> <volume>289</volume>(<issue>23</issue>): <fpage>3095</fpage>–<lpage>3105</lpage>.</citation></ref><ref id="c13" hwp:id="ref-13" hwp:rev-id="xref-ref-13-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Kessler RC"><surname>Kessler</surname> <given-names>RC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chiu WT"><surname>Chiu</surname> <given-names>WT</given-names></string-name>, <string-name name-style="western" hwp:sortable="Demler O"><surname>Demler</surname> <given-names>O</given-names></string-name>, <string-name name-style="western" hwp:sortable="Merikangas KR"><surname>Merikangas</surname> <given-names>KR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Walters EE"><surname>Walters</surname> <given-names>EE</given-names></string-name> (<year>2005</year>). <article-title hwp:id="article-title-14">Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication</article-title>. <source hwp:id="source-13">Arch Gen Psychiatry</source> <volume>62</volume>(<issue>6</issue>): <fpage>617</fpage>–<lpage>627</lpage>.</citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Krystal JH"><surname>Krystal</surname> <given-names>JH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Karper LP"><surname>Karper</surname> <given-names>LP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Seibyl JP"><surname>Seibyl</surname> <given-names>JP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Freeman GK"><surname>Freeman</surname> <given-names>GK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Delaney R"><surname>Delaney</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bremner JD"><surname>Bremner</surname> <given-names>JD</given-names></string-name>, <etal>et al</etal> (<year>1994</year>). <article-title hwp:id="article-title-15">Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psych otomimetic, perceptual, cognitive, and neuroendocrine responses</article-title>. <source hwp:id="source-14">Arch Gen Psychiatry</source> <volume>51</volume>(<issue>3</issue>): <fpage>199</fpage>–<lpage>214</lpage>.</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Krystal JH"><surname>Krystal</surname> <given-names>JH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sanacora G"><surname>Sanacora</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Duman RS"><surname>Duman</surname> <given-names>RS</given-names></string-name> (<year>2013</year>). <article-title hwp:id="article-title-16">Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond</article-title>. <source hwp:id="source-15">Biol Psychiatry</source> <volume>73</volume>(<issue>12</issue>): <fpage>1133</fpage>–<lpage>1141</lpage>.</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.16" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Lepack AE"><surname>Lepack</surname> <given-names>AE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fuchikami M"><surname>Fuchikami</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dwyer JM"><surname>Dwyer</surname> <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Banasr M"><surname>Banasr</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Duman RS"><surname>Duman</surname> <given-names>RS</given-names></string-name> (<year>2014</year>). <article-title hwp:id="article-title-17">BDNF release is required for the behavioral actions of ketamine</article-title>. <source hwp:id="source-16">Int J Neuropsychopharmacol</source> <volume>18</volume>(<issue>1</issue>).</citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1 xref-ref-17-2 xref-ref-17-3 xref-ref-17-4 xref-ref-17-5"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Li N"><surname>Li</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lee B"><surname>Lee</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liu RJ"><surname>Liu</surname> <given-names>RJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Banasr M"><surname>Banasr</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dwyer JM"><surname>Dwyer</surname> <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Iwata M"><surname>Iwata</surname> <given-names>M</given-names></string-name>, <etal>et al</etal> (<year>2010</year>). <article-title hwp:id="article-title-18">mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists</article-title>. <source hwp:id="source-17">Science</source> <volume>329</volume>(<issue>5994</issue>): <fpage>959</fpage>–<lpage>964</lpage>.</citation></ref><ref id="c18" hwp:id="ref-18" hwp:rev-id="xref-ref-18-1 xref-ref-18-2 xref-ref-18-3"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.18" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="Li N"><surname>Li</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liu RJ"><surname>Liu</surname> <given-names>RJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dwyer JM"><surname>Dwyer</surname> <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Banasr M"><surname>Banasr</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lee B"><surname>Lee</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Son H"><surname>Son</surname> <given-names>H</given-names></string-name>, <etal>et al</etal> (<year>2011</year>). <article-title hwp:id="article-title-19">Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure</article-title>. <source hwp:id="source-18">Biol Psychiatry</source> <volume>69</volume>(<issue>8</issue>): <fpage>754</fpage>–<lpage>761</lpage>.</citation></ref><ref id="c19" hwp:id="ref-19" hwp:rev-id="xref-ref-19-1 xref-ref-19-2"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.19" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Liu RJ"><surname>Liu</surname> <given-names>RJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lee FS"><surname>Lee</surname> <given-names>FS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Li XY"><surname>Li</surname> <given-names>XY</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bambico F"><surname>Bambico</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Duman RS"><surname>Duman</surname> <given-names>RS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Aghajanian GK"><surname>Aghajanian</surname> <given-names>GK</given-names></string-name> (<year>2012</year>). <article-title hwp:id="article-title-20">Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex</article-title>. <source hwp:id="source-19">Biol Psychiatry</source> <volume>71</volume>(<issue>11</issue>): <fpage>996</fpage>–<lpage>1005</lpage>.</citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1 xref-ref-20-2"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.20" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Lur G"><surname>Lur</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Higley MJ"><surname>Higley</surname> <given-names>MJ</given-names></string-name> (<year>2015</year>). <article-title hwp:id="article-title-21">Glutamate Receptor Modulation Is Restricted to Synaptic Microdomains</article-title>. <source hwp:id="source-20">Cell Rep</source> <volume>12</volume>(<issue>2</issue>): <fpage>326</fpage>–<lpage>334</lpage>.</citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="MacDonald JF"><surname>MacDonald</surname> <given-names>JF</given-names></string-name>, <string-name name-style="western" hwp:sortable="Miljkovic Z"><surname>Miljkovic</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pennefather P"><surname>Pennefather</surname> <given-names>P</given-names></string-name> (<year>1987</year>). <article-title hwp:id="article-title-22">Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine</article-title>. <source hwp:id="source-21">J Neurophysiol</source> <volume>58</volume>(<issue>2</issue>): <fpage>251</fpage>–<lpage>266</lpage>.</citation></ref><ref id="c22" hwp:id="ref-22" hwp:rev-id="xref-ref-22-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.22" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Mathew SJ"><surname>Mathew</surname> <given-names>SJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shah A"><surname>Shah</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lapidus K"><surname>Lapidus</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Clark C"><surname>Clark</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jarun N"><surname>Jarun</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ostermeyer B"><surname>Ostermeyer</surname> <given-names>B</given-names></string-name>, <etal>et al</etal> (<year>2012</year>). <article-title hwp:id="article-title-23">Ketamine for treatment-resistant unipolar depression: current evidence</article-title>. <source hwp:id="source-22">CNS Drugs</source> <volume>26</volume>(<issue>3</issue>): <fpage>189</fpage>–<lpage>204</lpage>.</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Mineur YS"><surname>Mineur</surname> <given-names>YS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bentham MP"><surname>Bentham</surname> <given-names>MP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhou WL"><surname>Zhou</surname> <given-names>WL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Plantenga ME"><surname>Plantenga</surname> <given-names>ME</given-names></string-name>, <string-name name-style="western" hwp:sortable="McKee SA"><surname>McKee</surname> <given-names>SA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Picciotto MR"><surname>Picciotto</surname> <given-names>MR</given-names></string-name> (<year>2015</year>). <article-title hwp:id="article-title-24">Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice</article-title>. <source hwp:id="source-23">Psychopharmacology (Berl)</source> <volume>232</volume>(<issue>19</issue>): <fpage>3539</fpage>–<lpage>3549</lpage>.</citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.24" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Moghaddam B"><surname>Moghaddam</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Adams B"><surname>Adams</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Verma A"><surname>Verma</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Daly D"><surname>Daly</surname> <given-names>D</given-names></string-name> (<year>1997</year>). <article-title hwp:id="article-title-25">Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex</article-title>. <source hwp:id="source-24">J Neurosci</source> <volume>17</volume>(<issue>8</issue>): <fpage>2921</fpage>–<lpage>2927</lpage>.</citation></ref><ref id="c25" hwp:id="ref-25" hwp:rev-id="xref-ref-25-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.25" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="Pologruto TA"><surname>Pologruto</surname> <given-names>TA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sabatini BL"><surname>Sabatini</surname> <given-names>BL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Svoboda K"><surname>Svoboda</surname> <given-names>K</given-names></string-name> (<year>2003</year>). <article-title hwp:id="article-title-26">ScanImage: flexible software for operating laser scanning microscopes</article-title>. <source hwp:id="source-25">Biomed Eng Online</source> <volume>2</volume>: <fpage>13</fpage>.</citation></ref><ref id="c26" hwp:id="ref-26" hwp:rev-id="xref-ref-26-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.26" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Ramos BP"><surname>Ramos</surname> <given-names>BP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Arnsten AF"><surname>Arnsten</surname> <given-names>AF</given-names></string-name> (<year>2007</year>). <article-title hwp:id="article-title-27">Adrenergic pharmacology and cognition: focus on the prefrontal cortex</article-title>. <source hwp:id="source-26">Pharmacol Ther</source> <volume>113</volume>(<issue>3</issue>): <fpage>523</fpage>–<lpage>536</lpage>.</citation></ref><ref id="c27" hwp:id="ref-27" hwp:rev-id="xref-ref-27-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Sleigh J"><surname>Sleigh</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Harvey M"><surname>Harvey</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Voss L"><surname>Voss</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Denny B"><surname>Denny</surname> <given-names>B</given-names></string-name> (<year>2014</year>). <article-title hwp:id="article-title-28">Ketamine – More mechanisms of action than just NMDA blockade</article-title>. <source hwp:id="source-27">Trends in Anaesthesia and Critical Care</source> <volume>4</volume>(<issue>2-3</issue>): <fpage>76</fpage>–<lpage>81</lpage>.</citation></ref><ref id="c28" hwp:id="ref-28" hwp:rev-id="xref-ref-28-1 xref-ref-28-2 xref-ref-28-3 xref-ref-28-4"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.28" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-28"><string-name name-style="western" hwp:sortable="Stratinaki M"><surname>Stratinaki</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Varidaki A"><surname>Varidaki</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mitsi V"><surname>Mitsi</surname> <given-names>V</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ghose S"><surname>Ghose</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Magida J"><surname>Magida</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dias C"><surname>Dias</surname> <given-names>C</given-names></string-name>, <etal>et al</etal> (<year>2013</year>). <article-title hwp:id="article-title-29">Regulator of G protein signaling 4 [corrected] is a crucial modulator of antidepressant drug action in depression and neuropathic pain models</article-title>. <source hwp:id="source-28">Proc Natl Acad Sci U S A</source> <volume>110</volume>(<issue>20</issue>): <fpage>8254</fpage>–<lpage>8259</lpage>.</citation></ref><ref id="c29" hwp:id="ref-29" hwp:rev-id="xref-ref-29-1 xref-ref-29-2"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.29" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-29"><string-name name-style="western" hwp:sortable="Takei N"><surname>Takei</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Inamura N"><surname>Inamura</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kawamura M"><surname>Kawamura</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Namba H"><surname>Namba</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hara K"><surname>Hara</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yonezawa K"><surname>Yonezawa</surname> <given-names>K</given-names></string-name>, <etal>et al</etal> (<year>2004</year>). <article-title hwp:id="article-title-30">Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites</article-title>. <source hwp:id="source-29">J Neurosci</source> <volume>24</volume>(<issue>44</issue>): <fpage>9760</fpage>–<lpage>9769</lpage>.</citation></ref><ref id="c30" hwp:id="ref-30" hwp:rev-id="xref-ref-30-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.30" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-30"><string-name name-style="western" hwp:sortable="Trivedi MH"><surname>Trivedi</surname> <given-names>MH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fava M"><surname>Fava</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wisniewski SR"><surname>Wisniewski</surname> <given-names>SR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Thase ME"><surname>Thase</surname> <given-names>ME</given-names></string-name>, <string-name name-style="western" hwp:sortable="Quitkin F"><surname>Quitkin</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Warden D"><surname>Warden</surname> <given-names>D</given-names></string-name>, <etal>et al</etal> (<year>2006</year>). <article-title hwp:id="article-title-31">Medication augmentation after the failure of SSRIs for depression</article-title>. <source hwp:id="source-30">N Engl J Med</source> <volume>354</volume>(<issue>12</issue>): <fpage>1243</fpage>–<lpage>1252</lpage>.</citation></ref><ref id="c31" hwp:id="ref-31" hwp:rev-id="xref-ref-31-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.31" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-31"><string-name name-style="western" hwp:sortable="Watson N"><surname>Watson</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Linder ME"><surname>Linder</surname> <given-names>ME</given-names></string-name>, <string-name name-style="western" hwp:sortable="Druey KM"><surname>Druey</surname> <given-names>KM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kehrl JH"><surname>Kehrl</surname> <given-names>JH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Blumer KJ"><surname>Blumer</surname> <given-names>KJ</given-names></string-name> (<year>1996</year>). <article-title hwp:id="article-title-32">RGS family members: GTPase-activating proteins for heterotrimeric G-protein alpha-subunits</article-title>. <source hwp:id="source-31">Nature</source> <volume>383</volume>(<issue>6596</issue>): <fpage>172</fpage>–<lpage>175</lpage>.</citation></ref><ref id="c32" hwp:id="ref-32" hwp:rev-id="xref-ref-32-1"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.32" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-32"><string-name name-style="western" hwp:sortable="Wohleb ES"><surname>Wohleb</surname> <given-names>ES</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gerhard D"><surname>Gerhard</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Thomas A"><surname>Thomas</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Duman RS"><surname>Duman</surname> <given-names>RS</given-names></string-name> (<year>2017</year>). <article-title hwp:id="article-title-33">Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine</article-title>. <source hwp:id="source-32">Curr Neuropharmacol</source> <volume>15</volume>(<issue>1</issue>): <fpage>11</fpage>–<lpage>20</lpage>.</citation></ref><ref id="c33" hwp:id="ref-33" hwp:rev-id="xref-ref-33-1 xref-ref-33-2"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.33" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-33"><string-name name-style="western" hwp:sortable="Zarate CA Jr"><surname>Zarate</surname> <given-names>CA</given-names>, <suffix>Jr</suffix></string-name>., <string-name name-style="western" hwp:sortable="Singh JB"><surname>Singh</surname> <given-names>JB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Carlson PJ"><surname>Carlson</surname> <given-names>PJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brutsche NE"><surname>Brutsche</surname> <given-names>NE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ameli R"><surname>Ameli</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Luckenbaugh DA"><surname>Luckenbaugh</surname> <given-names>DA</given-names></string-name>, <etal>et al</etal> (<year>2006</year>). <article-title hwp:id="article-title-34">A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression</article-title>. <source hwp:id="source-33">Arch Gen Psychiatry</source> <volume>63</volume>(<issue>8</issue>): <fpage>856</fpage>–<lpage>864</lpage>.</citation></ref><ref id="c34" hwp:id="ref-34" hwp:rev-id="xref-ref-34-1 xref-ref-34-2"><citation publication-type="journal" citation-type="journal" ref:id="341172v1.34" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-34"><string-name name-style="western" hwp:sortable="Zhong H"><surname>Zhong</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wade SM"><surname>Wade</surname> <given-names>SM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Woolf PJ"><surname>Woolf</surname> <given-names>PJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Linderman JJ"><surname>Linderman</surname> <given-names>JJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Traynor JR"><surname>Traynor</surname> <given-names>JR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Neubig RR"><surname>Neubig</surname> <given-names>RR</given-names></string-name> (<year>2003</year>). <article-title hwp:id="article-title-35">A spatial focusing model for G protein signals. Regulator of G protein signaling (RGS) protien-mediated kinetic scaffolding</article-title>. <source hwp:id="source-34">J Biol Chem</source> <volume>278</volume>(<issue>9</issue>): <fpage>7278</fpage>–<lpage>7284</lpage>.</citation></ref></ref-list></back></article>
